开发使用日本安全信息的药物安全信号检测参考集
Satoru Ito1,2, Mamoru Narukawa3
1Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan. satoru.itou.fh@kyowakirin.com.
Therapeutic innovation & regulatory science
|December 21, 2024
概括
使用日本药物安全数据开发了一个新的参考集,以评估药监数据挖掘方法. 这一组证明了更高的相关性,改善了在日本检测不良药物反应 (ADRs) 的情况.
科学领域:
- 药监和药物安全 药监和药物安全
- 在医疗保健中的数据挖掘.
- 监管科学 监管科学
背景情况:
- 药物监督旨在使用数据挖掘方法识别未知的不良药物反应 (ADR).
- 评估这些方法的现有参考集合缺乏日本特定的安全数据,这限制了它们在日本的适用性.
- 这需要开发一个以日本为中心的参考集,以准确检测ADR信号.
研究的目的:
- 根据日本药物安全信息开发和评估一套新的参考.
- 在日本的监管背景下,加强对ADR检测数据挖掘技术的绩效评估.
- 为了促进在日本批准和销售的药物的更可靠的信号识别.
主要方法:
- 使用43种药物和15种事件构建了一个参考组,并将日本风险管理计划 (J-RMP) 确定的风险纳入为正控.
- 负对照被定义为药物事件组合,在包装插件中未列为不良反应.
- 在日本药物不良事件报告数据库 (JADER) 上进行了数据挖掘,结果与开发的参考集进行了验证.
主要成果:
- 最终的参考组包括127个阳性和386个阴性对照.
- 与之前的研究相比,来自JADER的数据挖掘信号与这个新的参考集的相关性明显更高.
- 经验验证证证实了基于日本的参考集的有效性.
结论:
- 一个有价值的参考集,基于日本药物安全数据,已经成功开发.
- 该资源有望促进研究,提高日本药监数据采集方法的准确性.
- 该研究强调了区域特定数据对于强大的ADR信号检测的重要性.
更多相关视频
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
4.9K
17:28Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
12.6K
相关概念视频
01:19Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
01:12Hazard Ratio
87
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
87